Astra-Oxford Shot Produces Immune Response in Older Adults

A Covid vaccine candidate developed by the University of Oxford with AstraZeneca Plc has produced a robust immune response in older adults and the elderly, those at highest risk of severe illness.

Findings on blood tests carried out on a subset of older participants echo data released in July that showed the vaccine generated robust immune responses in healthy adults ages 18 to 55, Astra said Monday. Older patients have been hardest hit by the pandemic, with the vast majority of deaths occurring in those over 60.